Clinical trial · Interventional
Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma
Organochlorine Concentration in Adipose Tissue and Pancreatic Adenocarcinoma : a Case Control Study.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic adenocarcinoma represents more than 90% of pancreatic neoplasms. Around 14000 new cases of pancreatic adenocarcinoma are being diagnosed each year in France and about 8.6% in Grand Est region. National incidence has doubled for men and tripled for women between 1982 and 2012. Pancreatic adenocarcinoma is the deadliest digestive cancer, with only 7 to 8% all stages 5-year survival. It will become the second deadliest in Europe, behind bronchopulmonary cancer. Several risk factors have been identified such as diabetes, tobacco, chronic pancreatitis or obesity. However, a mismatch exists between incidence forecasts and actual risk factors knowledge. Several hypothesis plead for an environnemental cause. Plant protection products oncogenetic effects are known and have been proved to be responsible for tumors, including haematological malignancies. Its role in pancreatic carcinogenesis is still poorly studied and show heterogeneous results. They do not allow to conclude for causality. Organochlorines is a specific subset of plant protection product that store in lipids during lifetime. The aim is to study association between organochlorine concentration in adipose tissue with pancreatic adenocarcinoma.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Pancreatic Ductal | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adipose tissue sampling during surgery and urine sampling | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group "Cases"
- description
- patients with pancreatic adenocarcinoma
- interventionNames
- Other: Adipose tissue sampling during surgery and urine sampling
- type
- OTHER
- label
- Group "Controls"
- description
- patients without pancreatic adenocarcinoma
- interventionNames
- Other: Adipose tissue sampling during surgery and urine sampling
Primary outcomes (1)
- measure
- Adipose tissue organochlorine concentration
- timeFrame
- Day 0
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
inclusion criteria : Cases : * patients diagnosed with a pancreatic adenocarcinoma, all stages allowed * undergoing a surgery allowing to take a 10 grams adipose tissue sample Controls : * patients without a pancreatic neoplasm on a 6 months old CT scan before inclusion * undergoing a surgery allowing to take a 10 grams adipose tissue sample exclusion criteria : Cases : * patients diagnosed with a pancreatic adenocarcinoma developed on IPMN or cystadenoma * patient with a known genetic predisposition increasing pancreatic adenocarcinoma risk * histopathology proof of a mixed neuroendocrine neoplasm * no surgery allowing to take a 10 grams adipose tissue sample Controls : * patients with a pancreatic neoplasm on a 6 months old CT scan before inclusion * no surgery allowing to take a 10 grams adipose tissue sample
References
Publications (1)
- RESULTBrugel M, Callon S, Carlier C, Amroun KL, Botsen D, Kianmanesh R, Perrier M, Piardi T, Renard Y, Rhaiem R, El Balkhi S, Bouche O. Association between pancreatic adenocarcinoma risk and concentration of organochlorine pesticides in adipose tissue and urine: A targeted-screening analysis case-control study (PESTIPAC). United European Gastroenterol J. 2024 Sep;12(7):951-959. doi: 10.1002/ueg2.12602. Epub 2024 Aug 8. PMID 39118264